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Overview

The much-mooted field of personalised medicine has the potential to revolutionise the way in which we deliver care. However, like many burgeoning fields it abounds with futuristic rhetoric which has yet to be met with a commensurate improvement in patient care. Moreover, at up to US$300,000 per patient per annum the system wide implications of these disruptive innovations could even prove harmful. In this paper we seek to address the barriers experienced by stakeholders in integrating personalised medicines cost effectively into routine care. 

Introduction

Inter-individual variability in patients’ responses to medicines, including the likelihood of toxicity, is commonly due to differences in their genetic make-up1. Both problems present adverse care and resource issues, with non-response rates as high as 30-60%2. Resource issues include the cost of adverse reactions, which increase the number of hospital admissions, with the costs of emergency admissions in the UK due to adverse events estimated to be at least GB£2bn annually3. Resource issues are an increasing concern among health authorities with pharmaceutical expenditure growing faster than other components of ambulatory care, driven by ageing populations, rising patient expectations and the continued launch of new expensive drugs4. New premium priced medicines are being launched at over US$300,000 per year, often with only limited health gain versus current standards4,5.

Targeting valuable resources through personalisation is empirically an attractive proposition for health authorities or health insurers as it reduces the numbers needed to treat (NNT) and increases the numbers needed to harm (NNH), thereby improving the health gain for patients with available resources. It claims to deliver the right treatment to the right patient at the right time6. However, there are barriers which need to be addressed before personalised medicine becomes a reality. This article aims to stimulate this on-going debate and provide guidance for the future.

Personalised medicine is not new. For instance, GPs in the UK do not prescribe NSAIDs to patients with asthma as a matter of course. The guidelines for anti-hypertensives are predicated on knowledge of a patient’s race, age and comorbidities. When there are a few examples, physicians can memorise and integrate these into routine practice. However, as we dissect diseases beyond such phenotypic stratification, we find increasing examples of genetic differences in therapeutic responses some of which are already being exploited1, 7, 8, 9. This is resulting in a more heterogeneous spectrum of disease referred to by the recently coined ‘precision medicine’6. Ultimately, full personalisation of medicines will require a better understanding of the systems of genetic pathways rather than just single gene association, as demonstrated by the disappointing predictive yield of GWAS studies9. Having said this, the rapidity of new discoveries, drug targeting and of toxicity prediction has been made possible by greater knowledge of the human genome, which will continue. These developments will have a profound impact on the way in which drugs and diagnostic tests are being and will be developed, as well as the way physicians will practice medicine in the future2. This will include improved translation of biomarker test information into clinical practice, as well as improved understanding of whether one is dealing with diagnostic, screening or prognostic biomarkers. 

As this field of systems biology evolves with greater clinical utility in personalising therapy, the funding and policy environment must also evolve to facilitate the expediency with such therapies are introduced, used and evaluated in routine care2. Currently there are only relatively few clinical examples of personalised medicine being integrated into routine care, which has not been helped for instance by the current controversies surrounding the testing of patients prescribed clopidogrel or warfarin7,8,9. However, this is changing with recent research suggesting that 50% of the variability in the dosing of anti-coagulant therapy can be explained by genetic factors10. Overall, greater integration of personalised medicine into routine care will require new clinical trial structures, and innovative funding strategies which make it easier to fund new diagnostic drugs and any additional facilities along with potentially ‘valued’ drug therapy. Patient education will also be needed as the range of therapeutic options increases and becomes more complicated to navigate, requiring also the training of medical staff in lay language of genomics. 

Barriers

However for personalised medicine to become a greater reality, current barriers need to be appraised and addressed.

The fragmentation of the pharmaceutical market with increasing sub-populations is an understandable threat to the traditional business model of the pharmaceutical industry. However, the development and funding of new ‘blockbusters’ covering large patient numbers is becoming increasingly difficult as more standard drugs lose their patents, with the cost of generics as low as 2 to 3% of originator prices11. Increasing pressure on resources will also mean that the value of new drugs will come under greater scrutiny, especially if they are adding to choices rather than targeting real unmet need12.

Occasionally, events precipitate a retrospective search for personalisation, which was the case for the ‘Coxibs’ to reduce gastrointestinal bleeding compared with traditional NSAIDs12. The commercial value of identifying a genetic subgroup in which the pendulum swings towards a favourable outcome precipitated a search for single nucleotide polymorphisms (SNPs) to help predict therapeutic response. However, launch strategies appeared not to have been directed towards such an approach, which ultimately contributed to the demise of this drug class. As such practices increasingly become the norm it will be essential to develop policies which prevent, for example, the development of drugs whose effectiveness is maximal in ethnic groups which are enriched in affluent populations.

A major concern among health authorities and health insurance agencies though is that increased targeting of new drugs, resulting in increasingly smaller populations, will lead to some new drugs being considered as ‘orphan drugs’. As a result, companies will seek very high acquisition costs for their new drugs increasing the cost burden alongside the cost of the tests. This appears already to be happening with crizotinib and vermurafenib being launched at US$10,000 month excluding the cost of diagnostic tests, administration costs and other drugs to treat these patients, and US$25,000 for new drug to treat a small cohort of cystic fibrosis patients again excluding the costs of other treatments5. This at a time when the funding of cancer care is increasingly challenging for all countries. Consequently, pharmaceutical companies should seek to moderate their price expectations as without targeting, the value proposition of their new drugs would be appreciably reduced making it unlikely that high prices will be reimbursed especially in Europe.

The burgeoning field of genetic diagnostics is also becoming attractive commercially. However their integration into traditional models of care is currently not commonplace. This has resulted in private enterprises offering direct to consumer genetic testing. Whilst their penetration would historically be restricted to a small cadre of health seekers, such services are increasingly accessible via mobile software, which could be a worry with limited regulation. Ashley and colleagues recently demonstrated that personalised sequencing does yield clinically useful information13.  However, whilst companies such as deCodeme, 23 and me and Navigenetics could be considered the pragmatic vanguards of this phenomenon, and a case made for their role in driving this field into the clinic, there have been concerns regarding the lack of clinical utility of their outputs, discordance of results between companies, and test-related anxiety14. This mismatch between clinically interesting information, and its clinical utility, again demonstrates the major barriers that need to be addressed before their routine use in clinical practice. Further, the lack of clarity around the route to reimbursement for innovative diagnostics remains an incitement to caution amongst investors. Equally for Pharma, the incentives for developing their own diagnostics are limited by the risk of eroding existing profits through market segmentation.

At a health systems level, population health remains the critical driver of policy development. Health authorities are interested in drugs that are effective in an appreciable proportion of patients with a given disease, i.e. those with low NNTs, whereas individual patients wish for therapies which have a high of chance of working on them.  Consequently in the short term, the costs and associated infrastructure to instigate large-scale diagnostic facilities and testing may well be a barrier, and outsourcing may be a short-term possibility for new tests with proven clinical utility. This will also help address current deficiencies in staff training. However, this remains to be seen.

Lastly, patients can be forgiven for having an incomplete understanding of how to steer through the plethora of genetic developments. Where once longevity drove medical advance, and then a more focused measure taking into account patient reported outcomes in terms of for instance quality adjusted life years (QALYs), patients may soon have to navigate decisions based on their own personalised QALYs, e.g. which putative genetic risk do I want to mitigate against and at what cost? Unregulated, this could be the source of major anxiety14. However appropriately implemented, it could usher in a new development giving people the opportunity to live the life they chose15. 

Next steps – benefits of personalised medicine

What benefits could personalised medicine bring to commercial organisations, health systems, patients and practitioners? Despite the many challenges, the benefits for all key stakeholders are clear. For pharmaceutical companies, personalisation prior to the first phase III trials will reduce the likelihood of failure in drug development1. As such, there may need to be a rebalancing in the parameters in the current equation of drug development. If personalisation means less failure, then market fragmentation becomes less hazardous. Furthermore, the a priori use of pharmacogenomic approaches may reduce the costs of development by reducing the risk of not showing a clinically useful treatment. The model of effective medicines for niche markets was the foundation of Genzyme’s success, whose original orphan drug Ceredase was used to treat Gaucher’s disease, before being acquired by Sanofi-Aventis in 2011 for approximately US$20.1bn16. Where personalised medicine is gradually seeping into healthcare delivery; BRCA status in Breast and Ovarian Cancer, EGFR mutation status testing in Lung Cancer or the well documented BCR-ABL fusion protein in Chronic Myelogenous Leukemia, cautious lessons can increasingly be drawn on the indirect impact on outcomes and economics at a system level. 
 
As discussed, adverse drugs reactions account for between 5% to 10% of all acute hospital admissions at an estimated to cost the UK NHS of £2 billion annually3. In the US, admissions related to the complications of Warfarin alone cost on average $10,81917. The cost implications of prescribing drugs to patients with limited therapeutic effect also offer incentives to health systems to address this alongside reducing the costs of toxicities. However, this must be balanced against the resources in manpower and funding necessary for increased testing, as well as the concerns that new drugs for targeted sub-populations will increasingly be considered as orphan drugs with higher associated costs.

For individuals, improvements in effectiveness and reductions in toxicity should help to reduce anxiety with drug taking, and potentially improve compliance where toxicity is a concern18. Furthermore, improvements in personalised care is frequently demanded value by patient groups19.

For practioners, frequent therapeutic failure could lead to work stress and ultimately a more disenfranchised workforce20. Appropriate training in the delivery of personalised medicine, coupled with effective and appropriate system wide analysis, would limit the current lottery of clinical effectiveness and adverse events. The fall in NNTs would reduce the number of prescriptions and associated costs before a single patient benefits, a phenomenon which would be favoured by patients and providers alike.

Conclusions
There are causes for concern with the move towards personalised medicine including the avoidance of ethnically biased research and development although there appears little evidence of this to date. Genetic prejudice, commercial monopolies of the care of specific patient groups and escalating costs, especially if targeted therapies are priced similarly to current orphan drugs, are also causes for concern. However, progress in a manifestly ethical direction with an eye on the systemic implications and the potential to appreciably improve health within available resources should provide a stimulus to develop an environment in which the personalisation of medicine can flourish. The solutions lie across the spectre of stakeholders. 
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